Increase in cell motility by carbon ion irradiation via the Rho signaling pathway and its inhibition by the ROCK inhibitor Y-27632 in lung adenocarcinoma A549 cells

Kazutoshi MURATA1, Shin-ei NODA1,*, Takahiro OIKE1, Akihisa TAKAHASHI2, Yukari YOSHIDA3, Yoshiyuki SUZUKI1, Tatsuya OHNO3, Tomoo FUNAYAMA4, Yasuhiro KOBAYASHI4, Takeo TAKAHASHI5 and Takashi NAKANO1,3

1Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan
2Advanced Scientific Research Leaders Development Unit, Gunma University, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan
3Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan
4Microbeam Radiation Biology Group, Japan Atomic Energy Agency, Watanuki 1233, Takasaki, Gunma 370-1292, Japan
5Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe, Saitama 350-8550, Japan

*Corresponding author. Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan. Tel: +81-27-220-8383; Fax: +81-27-220-8397;
Email: snoda@gunma-u.ac.jp

(Received 19 August 2013; revised 8 December 2013; accepted 6 January 2014)

This study aimed to investigate the effect of carbon ion (C-ion) irradiation on cell motility through the ras homolog gene family member (Rho) signaling pathway in the human lung adenocarcinoma cell line A549. Cell motility was assessed by a wound-healing assay, and the formation of cell protrusions was evaluated by F-actin staining. Cell viability was examined by the WST-1 assay. The expression of myosin light chain 2 (MLC2) and the phosphorylation of MLC2 at Ser19 (P-MLC2-S19) were analyzed by Western blot. At 48 h after irradiation, the wound-healing assay demonstrated that migration was significantly greater in cells irradiated with C-ion (2 or 8 Gy) than in unirradiated cells. Similarly, F-actin staining showed that the formation of protrusions was significantly increased in cells irradiated with C-ion (2 or 8 Gy) compared with unirradiated cells. The observed increase in cell motility due to C-ion irradiation was similar to that observed due to X-ray irradiation. Western-blot analysis showed that C-ion irradiation (8 Gy) increased P-MLC2-S19 expression compared with in unirradiated controls, while total MLC2 expression was unchanged. Exposure to a non-toxic concentration of Y-27632, a specific inhibitor of Rho-associated coiled-coil-forming protein kinase (ROCK), reduced the expression of P-MLC2-S19 after C-ion irradiation (8 Gy), resulting in a significant reduction in migration. These data suggest that C-ion irradiation increases cell motility in A549 cells via the Rho signaling pathway and that ROCK inhibition reduces that effect.

Keywords: non-small cell lung carcinoma (NSCLC); cell motility; carbon ion (C-ion) irradiation; ras homolog gene family member (Rho); Rho-associated coiled-coil-forming protein kinase (ROCK)

INTRODUCTION

Non-small cell lung carcinoma (NSCLC) is one of the most lethal types of cancer, showing resistance to conventional radiation therapy (RT) [1]. Carbon ion (C-ion) RT is considered to be a promising treatment strategy for early-stage NSCLC because (i) C-ion RT is superior to conventional X-ray RT in dose distributions, with higher concentrations in tumors and superior normal tissue sparing that enables dose escalations, and (ii) a C-ion beam has a higher relative biological effectiveness (RBE) than that of X-rays. In fact, a previous study demonstrated favorable local control achieved by C-ion RT in patients with early-stage NSCLC [2]; however, another previous study documented cases with marginal...
recurrence after C-ion RT, which is an issue of great importance [3]. Marginal recurrence in C-ion RT may be due, in part, to insufficient dose delivery with a steep dose fall-off and susceptibility to set-up error and organ motion at the margin of tumors. Another possible cause for marginal recurrence is increased cancer-cell motility after irradiation. Several in vitro studies demonstrated that X-ray irradiation increased cell motility in cancer cells of various origins, including lung [4–6]. These reports indicate the possibility that cancer cells receiving X-ray irradiation may move outside of the radiation fields in clinical settings.

The increase in cancer-cell motility due to X-ray irradiation is achieved through the ras homolog gene family member (Rho) signaling pathway [5, 7]. In the Rho signaling pathway, Rho-associated coiled-coil-forming protein kinase (ROCK) is considered to act as an effector downstream of Rho [8]. ROCK directly and indirectly phosphorylates myosin light chain 2 (MLC2) at Ser19 (P-MLC2-S19), thereby increasing the contractility of actomyosin, which forms stress fibers and cell protrusions, resulting in cell migration. However, the effect of C-ion irradiation on motility in NSCLC cells and the underlying mechanisms have not been fully elucidated. Therefore, the present study investigated motility in A549 lung adenocarcinoma cells exposed to C-ion irradiation in vitro. The involvement of the Rho signaling pathway in radiation-induced motility was assessed using Y-27632, a specific inhibitor of ROCK [9].

MATERIALS AND METHODS

Cells and materials
A549 cells were purchased from the Cell Resources Center for Biomedical Research in Tohoku University (Sendai, Japan). The cells were cultured in RPMI-1640 (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum (ICN Biomedicals, OH, USA) at 37°C with 5% CO2. Y-27632, a specific inhibitor of ROCK, was purchased from Merck (Darmstadt, Germany).

Carbon ion and X-ray irradiation
C-ion irradiation was performed at the Takasaki Ion Accelerators for Advanced Radiation Application in the Japan Atomic Energy Agency (Gunma, Japan) or Gunma Heavy Ion Medical Center (Gunma, Japan). C-ion beams with a linear energy transfer of 108 keV/μm were used. The RBE of the C-ion irradiation in A549 cells at a 10% surviving fraction was calculated as 3.9 by a clonogenic survival assay (Supplementary Fig. 1).

WST-1 assay
To assess the viability of A549 cells, a WST-1 assay (Roche, Mannheim, Germany) was performed according to the manufacturer’s instructions. A549 cells were seeded on 96-well plates (1.0 × 10⁴ cells/well) and incubated at 37°C for 12 h. The cells received C-ion irradiation (0, 2 or 8 Gy) or continuous exposure to Y-27632 (0.01, 0.1, 1, 10 or 50 µM). After incubating for 24, 48, 72 or 120 h, 20 µl of WST-1 reagent was applied to each well. After incubating for an additional 3 h at 37°C, absorption of 450 nm light was measured using a Multiskan FC (Thermo, Helsinki, Finland).

Wound-healing assay
The motility of A549 cells was assessed by wound-healing assay, as previously described [7]. Briefly, A549 cells were cultured on 35-mm culture dishes to confluence. The monolayers were wounded by scratching with sterile pipette tips, rinsed once with culture medium, and then exposed to fresh culture medium. The cells were then subjected to C-ion irradiation (2 or 8 Gy) and incubated at 37°C for 2, 6, 12, 24 or 48 h. Phase-contrast images of the wounds were obtained at a × 20 magnification using a Real Surface View Microscope VE-7800 (Keyence, Osaka, Japan). For each wound, the distance between the nuclei of the cells located on the two edges of a wound was measured at 30 points in the vertical direction to the axis of the wound; the average value was defined as the width of the wound. The distance the cells migrated was calculated by subtracting the width of the wound measured at a given timepoint from that obtained 2 h after irradiation. To assess the effect of Y-27632, the cells were continuously exposed to 30 µM Y-27632 from 18 h before wounding to image acquisition.

F-actin staining
A549 cells seeded on coverslips were cultured for 18 h at 37°C to achieve 50% confluence, and then subjected (or not) to X-ray (8 Gy) or C-ion irradiation (2 or 8 Gy). After culturing
for a further 24 h, the cells were fixed with 3.7% paraformaldehyde for 10 min at room temperature, and permeabilized with 0.2% Triton X-100 for 5 min. The specimens were incubated with the actin stain 488 phalloidin (Cytoskeleton Inc., CO, USA) for 30 min at 37°C according to the manufacturer’s instruction, and counter-stained with DAPI for 5 min. To evaluate the formation of cell protrusions, the cells were imaged using a Real Surface View Microscope VE-7800 (Keyence) at a ×20 magnification. Five independent cell counts of at least 100 cells each were performed for each set of experimental conditions. The cells were counted by two researchers (K.M. and T.O.), blind to the experimental conditions, and evaluated for the formation of cell protrusions.

**Western-blot analysis**

A549 cells were cultured in the presence or absence of Y-27632 (30 µM) for 18 h and subjected (or not) to C-ion irradiation (2 or 8 Gy). After incubating for a further 0.5, 2 or 24 h at 37°C, the cells were harvested and lysed with cell lysis buffer (Millipore, MA, USA) containing phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, MO, USA) and protease inhibitor cocktail 3 (Calbiochem, Darmstadt, Germany). The protein lysates (50 µg) were subjected to electrophoresis on 15% mini-PROTEAN TGX precast gels (Bio-Rad, CA, USA) and transferred to nitrocellulose membranes (Bio-Rad). The membranes were incubated at room temperature for 1 h with PBST supplemented with 5% skimmed milk and exposed to primary and secondary antibodies. Primary antibodies specific for the following proteins were used: MLC2 (Cell Signaling Technology, MA, USA), P-MLC2-S19 (Cell Signaling Technology) and β-actin (Chemicon International, CA, USA). A polyclonal goat anti-mouse immunoglobulin (DAKO, CA, USA) was used as a secondary antibody. The Western blots were visualized using ECL chemiluminescent reagents (Bio-Rad) and ChemiStage CC16 mini (Wealtec, NV, USA).

**Statistics**

Significant differences were analyzed by an unpaired two-tailed Student’s t-test. *P* < 0.05 was considered significant. Results are expressed as the mean ± standard deviation (SD) of values obtained from at least three independent experiments. The error bars in the figures represent SDs.

**RESULTS**

**Carbon ion irradiation increased cell motility in A549 cells**

First we examined the effect of C-ion irradiation on the motility of A549 cells. Prior to the assessment of cell motility, the viability of C-ion-irradiated cells was assessed because differences in viability among cells receiving different doses of C-ion irradiation might affect the motility assessment. The WST-1 assay showed that the viability of the unirradiated cells increased from 24 to 120 h (Fig. 1). Meanwhile, C-ion irradiation (2 and 8 Gy) significantly reduced the cell viability 72 and 120 h after the irradiation (2 Gy, *P* = 0.0026 and 0.00070; 8 Gy, *P* = 0.013 and 0.0027, respectively); however, 48 h after receiving C-ion irradiation, there were no significant differences in viability between the irradiated and unirradiated cells (0 Gy vs 2 Gy, *P* = 0.22; 0 Gy vs 8 Gy, *P* = 0.49). As a result of these data, the assessment of cell motility was performed within 48 h after irradiation, a period when C-ion irradiation did not significantly affect cell viability.

![Fig. 2.](image-url) The effect of carbon ion (C-ion) and X-ray irradiation on cell motility in A549 cells assessed by a wound-healing assay. (a) Representative micrographs of the wounds observed 2 and 48 h after receiving C-ion irradiation. The arrow indicates the width of a wound. Scale bar, 200 µm. (b) Distances the cells migrated. Left panel, cells receiving C-ion irradiation; right panel, cells receiving X-ray irradiation. An asterisk indicates significant difference compared with the corresponding unirradiated control.
The effect of C-ion irradiation on cell motility was assessed by wound-healing assay (Fig. 2a and b). At 48 h after receiving C-ion irradiation for 0, 2 or 8 Gy, the distance the cells migrated was 534 ± 47, 640 ± 43 and 712 ± 56 µm, respectively. The migration distance was significantly greater in the cells irradiated with 2 and 8 Gy than in the unirradiated cells (P = 0.045 and 0.013, respectively). It appeared that there was a dose-dependence in the increase in cell motility.

Meanwhile, the wound-healing assay showed that X-ray irradiation also increased the motility of A549 cells (Fig. 2b). At 48 h after X-ray irradiation (2 and 8 Gy), when cell viability was not significantly affected (data not shown), the cells receiving 0, 2 and 8 Gy migrated 531.52 ± 23.67, 604.12 ± 16.55 and 637.58 ± 38.35 µm, respectively. The migration distance was significantly greater in the cells receiving X-ray irradiation (2 and 8 Gy) than in the unirradiated cells (P = 0.012 and 0.015, respectively).

To further investigate the effect of C-ion and X-ray irradiation on cell motility, we evaluated the formation of cell protrusions, another marker of motility [10], by F-actin staining. Interestingly, irradiation with both C-ion (2 and 8 Gy) and X-rays (8 Gy) significantly increased the formation of cell protrusions 24 h after irradiation compared with unirradiated controls (C-ion, P = 0.0026 and 0.000 039 for 2 and 8 Gy, respectively; X-rays, P = 0.000 28 for 8 Gy) (Fig. 3). Taken together, these data suggest that C-ion irradiation increases cell motility in A549 cells in a similar manner to X-rays.

**ROCK inhibition by Y-27632 suppressed the increase in motility in A549 cells after carbon ion irradiation**

The Rho signaling pathway is involved in the increase in cell motility after X-ray irradiation in A549 cells [7]. Therefore, the involvement of the Rho signaling pathway in the increase

---

**Fig. 3.** The effect of carbon ion (C-ion) and X-ray irradiation on the formation of cell protrusions in A549 cells assessed by F-actin staining. (a) Representative micrograph of non-treated control cells (upper panel), cells irradiated with X-rays for 8 Gy (middle panel), and those irradiated with C-ion for 8 Gy (lower panel) taken 24 h after irradiation at a ×40 magnification. F-actin and nuclei are shown in green (Alexa Fluor 488 phaloidin) and blue (DAPI), respectively. Scale bar, 30 µm. (b) Numbers of cells forming protrusions are shown. An asterisk indicates significant difference compared with the unirradiated control.
in cell motility after C-ion irradiation in A549 cells was investigated by Western blot. At 24 h after C-ion irradiation, increased P-MLC2-S19 expression was observed in cells irradiated with 8 Gy compared with unirradiated controls (Fig. 4a). Interestingly, the phosphorylation level of MLC2 increased in a time-dependent manner (Fig. 4b). These results indicate that activation of the Rho signaling pathway may contribute to the increase in cell motility in A549 cells receiving C-ion irradiation. Therefore, we investigated whether the inhibition of ROCK suppressed the increase in cell motility by C-ion irradiation using Y-27632, which is a specific inhibitor of ROCK. A WST-1 assay showed that there was no significant difference in the viability of the cells exposed to Y-27632 at concentrations ranging from 0.01 to 50 µM for 48 h (Fig. 5). From these results, 30 µM, a concentration at which Y-27632 does not affect cell viability, was used in subsequent analyses. Western-blot analysis showed that the expression of P-MLC2-S19 was reduced in all the samples exposed to Y-27632 (Fig. 4a). Of note, Y-27632 reduced the expression of P-MLC2-S19 in cells receiving C-ion (8 Gy) to a level similar to that observed in non-treated controls, indicating that Y-27632 suppressed signal transduction through the Rho/ROCK/MLC2 pathway activated after C-ion irradiation. Wound-healing assays revealed that Y-27632 significantly reduced the migration distance of the irradiated cells ($P = 0.049$ and 0.039 for 2 and 8 Gy, respectively) (Fig. 6). Taken together, these data indicate that inhibition of ROCK reduces the increase in cell motility after C-ion irradiation in A549 cells.

**DISCUSSION**

In the present study, wound-healing assays and F-actin staining showed that C-ion irradiation increased cell motility in A549 cells. It seems that the increase in cancer-cell motility after irradiation is not a characteristic of C-ion beams, but rather a phenomenon similar to what is observed after X-ray
radiation on the migration of cancer cells [11, 12]. In these, cells when used in combination with C-ion RT.

Inhibition may reduce the migration of the irradiated cancer A549 cells after C-ion irradiation, suggesting that ROCK inhibition by Y-27632, was involved in the increase in cell motility in the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage [16]. In this regard, if the involvement of the Rho/ROCK/MLC2 cascade in the increased cancer-cell motility after C-ion irradiation is proven, the finding can be directly applied in the clinic with fasudil treatment combined with C-ion RT for the prevention of cancer-cell migration after C-ion RT. However, fasudil is known to interact with multiple molecules such as free intracellular calcium ions and protein kinases A, G and C (16). Thus, in the present study, in order to clearly evaluate the effect of ROCK inhibition on cell motility after C-ion irradiation, the inhibitor Y-27632, which is specific for ROCK [17], was used instead of fasudil, even though Y-27632 is not suitable for human use. As a result, ROCK inhibition by Y-27632 resulted in the reduced motility in A549 cells irradiated with C-ion of 2 and 8 Gy by 20% and 25%, respectively (Fig. 6). These data indicate the potential of clinical ROCK inhibition on cancer-cell motility should be examined.

The Rho signaling pathway involving in the cell motility has many downstream effectors. Among them, in the present study, we selected the phosphorylation of MLC2 at Ser19 as an indicator of the activation of Rho signaling because it is well known that the Ser19 of MLC2 is specifically phosphorylated via ROCK [14], and that the resulting P-MLC2-S19 plays a pivotal role in cell motility through its interaction with actin–myosin [15]. There is a clinically available (intravenously administered) agent with ROCK inhibitory activity named fasudil (Daiichi Chemical and Pharmacological Company, Ibaragi, Japan), which is approved in Japan for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage [16]. In this regard, if the involvement of the Rho/ROCK/MLC2 cascade in the increased cancer-cell motility after C-ion irradiation is proven, the finding can be directly applied in the clinic with fasudil treatment combined with C-ion RT for the prevention of cancer-cell migration after C-ion RT. However, fasudil is known to interact with multiple molecules such as free intracellular calcium ions and protein kinases A, G and C (16). Thus, in the present study, in order to clearly evaluate the effect of ROCK inhibition on cell motility after C-ion irradiation, the inhibitor Y-27632, which is specific for ROCK [17], was used instead of fasudil, even though Y-27632 is not suitable for human use. As a result, ROCK inhibition by Y-27632 resulted in the reduced motility in A549 cells irradiated with C-ion of 2 and 8 Gy by 20% and 25%, respectively (Fig. 6). These data indicate the potential of clinical ROCK inhibition for the suppression of migration of cancer cells during and after C-ion RT. Taken together, fasudil combined with C-ion RT is an attractive method for improving local disease control that warrants investigation in the clinic.

The present study has several limitations. In a wound-healing assay, only the motility of cells at the edge of scratched wounds can be evaluated. In contrast, in F-actin staining, cells seeded on coverslips at 50% confluence showed increased cell protrusions, indicating that C-ion irradiation increased cell motility not only in cells living on the edge of tumors, but also in those living at the center of a cluster of cancer cells. Nevertheless, these results are not

Fig. 6. The effect of Y-27632 on motility in A549 cells after C-ion irradiation assessed by a wound-healing assay. The cells were exposed to Y-27632 (30 µM) for 18 h and subjected to a wound-healing assay as in Fig. 2. The cells were kept exposed to Y-27632 until the time of assessment. For each of the samples treated with or without Y-27632, the migration distances were measured for the suppression of migration of cancer cells during and after C-ion RT. Taken together, fasudil combined with C-ion RT is an attractive method for improving local disease control that warrants investigation in the clinic.
enough to completely understand the spatio-temporal effect of C-ion irradiation on cancer-cell motility. The present study also investigated the effect of C-ion irradiation on cancer-cell motility within 48 h after irradiation, when C-ion irradiation did not significantly affect cell viability, in order to focus on motility; however, in the clinical setting the situation can be more complicated because the repopulation of the irradiated cancer cells may affect their motility. To clarify these issues, analyses using 3D tumor models such as in vitro spheroids or in vivo mouse xenograft tumor models should be performed in the future. Furthermore, the mechanism underlying the continuous phosphorylation of MLC2-S19 after C-ion irradiation is largely unknown and warrants further investigation.

CONCLUSION

In conclusion, the present study showed that C-ion irradiation increased cell motility in A549 cells via the Rho/ROCK/MLC2 signaling pathway, and that inhibition of ROCK reduced the increase in cell motility in irradiated cells. Further investigation will elucidate the effect of C-ion irradiation on migration, invasion and metastasis, and the underlying mechanism, which will help to develop efficient treatment strategies in C-ion RT.

SUPPLEMENTARY DATA

Supplementary data is available at the Journal of Radiation Research online.

FUNDING

This work was supported by Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science Grant Number 25861071.

REFERENCES

1. Rosenzweig KE, Sura S, Jackson A et al. Involved-field radiation therapy for inoperable non–small-cell lung cancer. J Clin Oncol 2007;25:5557–61.
2. Miyamoto T, Baba M, Yamamoto N et al. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007;67:750–8.
3. Koto M, Miyamoto T, Yamamoto N et al. Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol 2004;71:147–56.
4. Cordes N, Meineke V. Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 2003;179:337–44.
5. Fujita M, Otsuka Y, Yamada S et al. X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer Sci 2011;102:792–8.
6. Zhai GG, Malhotra R, Delaney M et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006;76:227–37.
7. Zhu F, Zhang Z, Wu G et al. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 2011;28:565–71.
8. Nakagawa O, Fujisawa K, Ishizaki T et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189–93.
9. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990–4.
10. Machacek M, Hodgson L, Welch C et al. Coordination of Rho GTPase activities during cell protrusion. Nature 2009;461:99–103.
11. Goetze K, Scholz M, Taucher-Scholz G et al. The impact of conventional and heavy ion irradiation on tumor cell migration in vitro. Int J Radiat Biol 2007;83:889–96.
12. Akino Y, Teshima T, Kihara A et al. Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2009;75:475–81.
13. Wie LH, Lai KP, Chen CA et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB. Oncogene 2003;25:390–8.
14. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11:471–7.
15. Amano M, Ito M, Kimura K et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271:20246–9.
16. Shibuya M, Suzuki Y, Sugita K et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571–7.
17. Honjo M, Tanihara H, Inatani M et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137–44.